Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year?
Here is how HeartSciences Inc. (HSCS) and ImmunityBio (IBRX) have performed compared to their sector so far this year.
Equity
ImmunityBio, Inc. (IBRX) Stock — Today's Move
$7.81
$-0.41 today
IBRX is down 4.99% today. Volume is 10.96M vs a 30-day average of 14.99M (0.73x).
Day High
$8.28
Day Low
$7.75
Open
$8.23
Prev Close
$8.22
Volume
10.96M
Avg Vol (30d)
14.99M
52-Wk High
$12.43
52-Wk Low
$1.95
Sector
—
Today's Move
-4.99%
Next Earnings
Thu, Nov 5
ImmunityBio, Inc. is scheduled to report earnings Thu, Nov 5, 2026. Analysts expect EPS of $-0.09 on revenue of about $60.44M. Stocks often move sharply on earnings day.
52-wk low $1.9552-wk high $12.43
IBRX is 56% of the way from its 52-week low to its high.
Indicators:
Close price · volume bars (dashed line = average volume) · news that day (2M–1Y) — hover or tap the chart. Indicators are for education, not trading advice.
Why is IBRX moving today?
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
CULVER CITY, Calif., October 21, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced completion of the database lock for Cohort A of QUILT-2.005 (NCT…
ImmunityBio: Not Executing At The Level That The Market Is Pricing In
ImmunityBio, Inc. outlook: Anktiva label expansion lifts sales, but cash burn and rich valuation raise risk. Click for this IBRX stock update.
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
CULVER CITY, Calif., October 16, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase…
ImmunityBio Announces Data From Its Phase 2/3 QUILT-3.032 Trial Of ANKTIVA In Combination With Bacillus Calmette-Guerin Demonstrates 71% Complete Response Rate In Participants With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ
ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Journal …
Related Movers
XP
▼ -48.36%
XP Inc.
Gap Stock Movers: SGRY Leads Gap-Ups and XP Leads Gap-Downs in Today's Session
$15.71
-$14.71
INTR
▼ -34.91%
Inter & Co. Inc.
S&P Index Addition Could Change The Case For Inter (INTR) Stock
$4.68
-$2.51
BBD
▼ -28.01%
Banco Bradesco Sa
Most Active Stocks on Oct. 26: RCT, NU and BBD Top Volume
$2.93
-$1.14
SBS
▼ -26.09%
Companhia de saneamento Basico
$4.73
-$1.67
FAQ — IBRX
Why is IBRX moving today?
IBRX is down 4.99% in the current session. Scroll to the news section below to see the most recent headlines and catalysts driving the move.
Is ImmunityBio, Inc. a good stock to buy today?
WeeklyTrader.io does not provide financial advice. Always verify catalysts, assess risk, and conduct your own research before making any investment decision.
What is IBRX's average volume?
Average volume for IBRX is approximately 14.99M shares per day based on the trailing 30 sessions.